c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma

OncoImmunology

Volumn 4, Issue 2, 2015, Pages 1-10

  Kumai, Takumi ^a,b   Matsuda, Yoshinari ^a   Ohkuri, Takayuki ^a   Oikawa, Kensuke ^a   Ishibashi, Kei ^a   Aoki, Naoko ^a   Kimura, Shoji ^a   Harabuchi, Yasuaki ^a   Celis, Esteban ^b   Kobayashi, Hiroya ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Autophagy; C Met; CD4+ helper T lymphocytes; Head and neck squamous cell carcinoma; Immunotherapy; Major histo compatibility complex class II; NK T cell lymphoma; TGF ; Tumor antigens

Indexed keywords

3 METHYLADENINE; CELL SURFACE RECEPTOR; CHAPERONE; HEAT SHOCK PROTEIN 70; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEROXIDASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SYNTHETIC PEPTIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; VALPROIC ACID;

ARTICLE; AUTOPHAGY; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL DEATH; CELL LYSATE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; EPITHELIUM TUMOR; GENE EXPRESSION; HELPER CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MTT ASSAY; NK T CELL LYMPHOMA; T LYMPHOCYTE; TUMOR CELL; TUMOR ESCAPE; WESTERN BLOTTING;

EID: 84946590578     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.976077     Document Type: Article

References (30)

1. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992; 140:769-74; PMID:1314023; PMCID: PMC1886378
2. Harabuchi Y, Imai S, Wakashima J, Hirao M, Kataura A, Osato T, Kon S. Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studies. Cancer 1996; 77:2137-49; PMID:8640683; http://dx.doi.org/10.1002/(SICI)1097-0142(19960515)77:10%3c2137::AID-CNCR27%3e3.0.CO;2-V
3. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashi- moto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011; 29:4410-6; PMID:21990393; http://dx.doi.org/10.1200/JCO.2011.35.6287
4. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 2009; 15:3740-50; PMID:19470725; http://dx.doi.org/10.1158/1078-0432.CCR-08-3252
5. Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, Pals ST. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003; 17:764-74; PMID:12682635; http://dx.doi.org/10.1038/sj.leu.2402875
6. Canadas I, Rojo F, Taus A, Arpi O, Arumi-Uria M, Pijuan L, Menendez S, Zazo S, Domine M, Salido M et al. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res 2014; 20:938-50; PMID:24284055; http://dx.doi.org/10.1158/1078-0432.CCR-13-1330
7. Schag K, Schmidt SM, Muller MR, Weinschenk T, Appel S, Weck MM, Grunebach F, Stevanovic S, Ram- mensee HG, Brossart P. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin Cancer Res 2004; 10:3658-66; PMID:15173072; http://dx.doi.org/10.1158/1078-0432.CCR-03-0640
8. Mortenson ED, Park S, Jiang Z, Wang S, Fu YX. Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res 2013; 19:1476-86; PMID:23363817; http://dx.doi.org/10.1158/1078-0432.CCR-12-2522
9. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002; 8:620-7; PMID:11839685
10. Kumai T, Ishibashi K, Oikawa K, Matsuda Y, Aoki N, Kimura S, Hayashi S, Kitada M, Harabuchi Y, Celis E et al. Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53. Cancer Immunol Immunother 2014; 63 (5):469-78; PMID:24633296; http://dx.doi.org/10.1007/s00262-014-1533-z
11. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/jimmuni.2013.07.012
12. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011; 10:1533-41; PMID:21878654; http://dx.doi.org/10.1158/1535-7163.MCT-11-0047
13. Miyajima N, Tsutsumi S, Sourbier C, Beebe K, Molla-pour M, Rivas C, Yoshida S, Trepel JB, Huang Y, Tatokoro M et al. The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. Cancer Res 2013; 73:7022-33; PMID:24121490; http://dx.doi.org/10.1158/0008-5472.CAN-13-1156
14. Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res 2008; 68:6889-95; PMID:18757401; http://dx.doi.org/10.1158/0008-5472.CAN-08-0161
15. Iwata S, Saito T, Ito Y, Kamakura M, Gotoh K, Kawada J, Nishiyama Y, Kimura H. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells. Cancer Sci 2012; 103:375-81; PMID:22017376; http://dx.doi.org/10.1111/j.1349-7006.2011.02127.x
16. Murata T, Iwata S, Siddiquey MN, Kanazawa T, Gosh- ima F, Kawashima D, Kimura H, Tsurumi T. Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma. PloS one 2013; 8:e63566.
17. Blumenschein GR, Jr., Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J clinical oncol 2012; 30:328796; PMID:22869872; http://dx.doi.org/10.1200/JCO.2011.40.3774
18. Kang YK, Muro K, Ryu MH, Yasui H, Nishina T, Ryoo BY, Kamiya Y, Akinaga S, Boku N. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs 2014; 32:355-61; PMID:24337769; http://dx.doi.org/10.1007/s10637-013-0057-2
19. Brauer HA, Makowski L, Hoadley KA, Casbas-Her-nandez P, Lang LJ, Roman-Perez E, D’Arcy M, Free- merman AJ, Perou CM, Troester MA. Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clin Cancer Res 2013; 19:571-85; PMID:23236214; http://dx.doi.org/10.1158/1078-0432.CCR-12-2123
20. Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, Kitada M, Tateno M, Celis E, Kobayashi H. Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeu- tic targets for lung cancer. J Transl Med 2011; 9:191; PMID:22053850; http://dx.doi.org/10.1186/1479-5876-9-191
21. Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F et al. Limited induction of tumor crossreactive T cells without a measurable clinical benefit inearly melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res 2012; 18:6485-96; PMID:23032742; http://dx.doi.org/10.1158/1078-0432.CCR-12-1516
22. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008; 14:797-803; PMID:18245541
23. Kwong YL, Chan AC, Liang R, Chiang AK, Chim CS, Chan TK, Todd D, Ho FC. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97:821-9; PMID:9217183; http://dx.doi.org/10.1046/j.1365-2141.1997.1462962.x
24. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86; PMID:14676299; http://dx.doi.org/10.1084/jem.20030152
25. Kumai T, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. Tumor-derived TGF-ss and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor. J Transl Med 2014; 12:265; PMID:25240937; http://dx.doi.org/10.1186/s12967-014-0265-3
26. Tsan MF, Gao B. Heat shock proteins and immune system. J Leukoc Biol 2009; 85:905-10; PMID:19276179; http://dx.doi.org/10.1189/jlb.0109005
27. Nagata H, Konno A, Kimura N, Zhang Y, Kimura M, Demachi A, Sekine T, Yamamoto K, Shimizu N. Characterization of novel natural killer (NK)-cell and gam- madelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood 2001; 97:708-13; PMID:11157488; http://dx.doi.org/10.1182/blood.V97.3.708
28. Tsuge I, Morishima T, Morita M, Kimura H, Kuzush- ima K, Matsuoka H. Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Clin Exp Immunol 1999; 115:385-92; PMID:10193407; http://dx.doi.org/10.1046/j.1365-2249.1999.00836.x
29. Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, Harabuchi Y. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metas- tases and prognosis. Clin Cancer Res 2004; 10:634-40; PMID:14760086; http://dx.doi.org/10.1158/1078-0432.CCR-0864-02
30. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998; 160:3363-73; PMID:9531296